Michael Miller, MD

Cardiology
Accepting new patients
Sees patients age 18 and up
Penn Heart and Vascular Center
Schedule onlineCall 215-615-4949
Headshot of Michael Miller, MD
Penn Medicine Provider

About me

  • Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania

Dr. Michael Miller is a cardiologist at Penn Medicine with a notable interest in preventive cardiology. He specializes in the prevention of heart disease, focusing on risk assessment, lipid (cholesterol and triglyceride) management and lifestyle modification. He is a lecturer for the Perelman School of Medicine Foundations of Culinary Medicine. He has conducted research on the effects of diet and emotional health on inflammation and vascular function with multiple publications on this topic. Dr. Miller is the author of “Heal Your Heart…” (Penguin Random-House), and co-author of “The American Medical Association Guide to Preventing and Treating Heart Disease (American Medical Association)” and “The Practice of Coronary Disease Prevention” (Lippincott, Williams & Wilkins). 

My education and training

  • Medical School: Robert Wood Johnson University Hospital
  • Residency: University of Cincinnati Medical Center
  • Fellowship: Johns Hopkins University School of Medicine
  • Fellowship: Johns Hopkins Hospital

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Miller is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Gurevitz C, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Lira Pineda A, Doyle RT Jr, Giugliano G, Mason RP, Tardif JC, Martens FMAC, Ballantyne CM, Budoff MJ, Gibson CM Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT , Eur J Prev Cardiol: 2026

Miller M, Aggarwal M, Allen K, Bhattacharya R, Dastmalchi LN, Kris-Etherton PM, Klodas E, Mazaffarian D, Ostfeld RJ, Petersen KS, Reddy KR, Ros E, Vinaithirthan V, Freeman AM A Clinician’s Guide for Trending Cardiovascular Nutritional Controversies in 2026 , Journal of the American College of Cardiology Advances: 2026

Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S. Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. , Cardiology, 150: 2025,194-202

Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Ketchum S, Pineda AL, Tardif J-C, Ballantyne CM on Behalf of the Reduce-IT Investigators Icosapent Ethyl Reduces CVD Risk in Cardiovascular-Kidney-Metabolic Syndrome: REDUCE-IT CKM , American Journal of Preventive Cardiology: 2025

Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN. Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. , Journal of Clinical lipidology: 2025

Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton E, Dunbar R, Ketchum S, Tardif J-C, Martens F, Ballantyne CM, Szarek M, Mason RP. Cardiovascular Outcomes with Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. , JAHA: Journal of the American Heart Association.: 2025

Zisman E, Hossain M, Funderburg NT, Christenson R, Jeudy J, Burrowes S, Hays AG, George N, Freeman ML, Rebuck H, Mitchell SE, Miller M, Bagchi S. Association of Lipoprotein (a) with peri-coronary inflammation in persons with and without HIV infection , J Clin Lipidol: 2024

Sayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. , Eur Heart J. : 2024

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. , J Am Heart Assoc, 13: 2024

Miller M Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. , Curr Opin Cardiol: 2024